NASDAQ:MGNX - MacroGenics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$23.51 +0.56 (+2.44 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$22.95
Today's Range$23.01 - $23.54
52-Week Range$14.36 - $32.74
Volume314,808 shs
Average Volume339,764 shs
Market Capitalization$946.59 million
P/E Ratio-43.52
Dividend YieldN/A
Beta2.45
MacroGenics logoMacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It is also developing Flotetuzumab, a DART molecule that targets CD123 and CD3; MGA012, a monoclonal antibody, which targets programmed cell death protein 1 (PD-1); MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; MGD019, a preclinical DART molecule designed to recognize the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company develops MGD009, a DART molecule recognizes B7-H3 and CD3; MGC018, a B7-H3 antibody-drug conjugate; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; and MGD014, a DART molecule that targets the envelope protein of human immunodeficiency virus, or HIV-infected cells and CD3-expressing T cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGNX
CUSIPN/A
Phone301-251-5172

Debt

Debt-to-Equity RatioN/A
Current Ratio5.43
Quick Ratio5.43

Price-To-Earnings

Trailing P/E Ratio-43.52
Forward P/E Ratio-4.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$157.74 million
Price / Sales6.29
Cash FlowN/A
Price / CashN/A
Book Value$8.13 per share
Price / Book2.89

Profitability

EPS (Most Recent Fiscal Year)($0.54)
Net Income$-19,620,000.00
Net Margins-19.64%
Return on Equity-13.03%
Return on Assets-10.36%

Miscellaneous

Employees330
Outstanding Shares42,200,000

MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How were MacroGenics' earnings last quarter?

MacroGenics (NASDAQ:MGNX) released its quarterly earnings results on Monday, May, 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.08) by $0.26. The biopharmaceutical company had revenue of $4.70 million for the quarter, compared to the consensus estimate of $7.46 million. MacroGenics had a negative return on equity of 13.03% and a negative net margin of 19.64%. View MacroGenics' Earnings History.

What price target have analysts set for MGNX?

11 equities research analysts have issued 1 year target prices for MacroGenics' stock. Their predictions range from $22.00 to $44.00. On average, they expect MacroGenics' stock price to reach $31.50 in the next year. View Analyst Ratings for MacroGenics.

What are Wall Street analysts saying about MacroGenics stock?

Here are some recent quotes from research analysts about MacroGenics stock:
  • 1. HC Wainwright analysts commented, "We are currently not valuing the B7-H3 franchise pending clinical updates on the combination program with Keytruda and preliminary read from the B7-H3 x CD3 DART molecule, which if positive could rival the remainder of the pipeline in terms of clinical importance. Risks potentially incurred investing in this stock include: clinical and development, financial, regulatory and reimbursement, and commercial." (6/4/2018)
  • 2. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (5/9/2018)

Who are some of MacroGenics' key competitors?

Who are MacroGenics' key executives?

MacroGenics' management team includes the folowing people:
  • Dr. Scott Koenig, CEO, Pres & Director (Age 66)
  • Mr. James Karrels, Sr. VP, CFO & Sec. (Age 51)
  • Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 64)
  • Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 45)
  • Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 56)

Has MacroGenics been receiving favorable news coverage?

Press coverage about MGNX stock has trended positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MacroGenics earned a coverage optimism score of 0.44 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 47.78 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include OppenheimerFunds Inc. (9.36%), BlackRock Inc. (6.32%), Wasatch Advisors Inc. (2.42%), Millennium Management LLC (2.13%), Pinnacle Associates Ltd. (1.87%) and Hood River Capital Management LLC (1.54%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jon Marc Wigginton and Lynn Cilinski. View Institutional Ownership Trends for MacroGenics.

Which major investors are selling MacroGenics stock?

MGNX stock was sold by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Prosight Management LP, DAFNA Capital Management LLC, Pinnacle Associates Ltd., Wasatch Advisors Inc., Sphera Funds Management LTD. and Legal & General Group Plc. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, James Karrels, Jon Marc Wigginton and Lynn Cilinski. View Insider Buying and Selling for MacroGenics.

Which major investors are buying MacroGenics stock?

MGNX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Victory Capital Management Inc., CVI Holdings LLC, Spark Investment Management LLC, Dynamic Technology Lab Private Ltd, Rock Springs Capital Management LP, Landscape Capital Management L.L.C. and Citadel Advisors LLC. View Insider Buying and Selling for MacroGenics.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $23.51.

How big of a company is MacroGenics?

MacroGenics has a market capitalization of $946.59 million and generates $157.74 million in revenue each year. The biopharmaceutical company earns $-19,620,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. MacroGenics employs 330 workers across the globe.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.


MarketBeat Community Rating for MacroGenics (MGNX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  435
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.